title: Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma.
abstract: Considerable effort has been spent identifying prognostic biomarkers in classic Hodgkin lymphoma (cHL). The aim of our study was to search for possible prognostic parameters in advanced-stage cHL using a proteomics-based strategy. A total of 14 cHL pretreatment tissue samples from younger, advanced-stage patients were included. Patients were grouped according to treatment response. Proteins that were differentially expressed between the groups were analyzed using 2D-PAGE and identified by liquid chromatography mass spectrometry. Selected proteins were validated using Western blot analysis. One of the differentially expressed proteins, the carbohydrate-binding protein galectin-1 (Gal-1), was further analyzed using immunohistochemistry HC and its expression was correlated with clinicopathologic and outcome parameters in 143 advanced-stage cHL cases. At the univariate level, high Gal-1 expression in the tumor microenvironment was correlated with poor event-free survival (P = .02). Among younger (≤ 61 years) patients, high Gal-1 was correlated with poorer overall and event-free survival (both P = .007). In this patient group and at the multivariate level, high Gal-1 expression retained a significant predictive impact on event-free survival. Therefore, in addition to its functional role in cHL-induced immunosuppression, Gal-1 is also associated with an adverse clinical outcome in this disease.
authors.affiliation: Department of Hematology, Arhus University Hospital, Tage Hansens Gade 2, Aarhus C, Denmark. petekamp@rm.dk
authors.forename: Peter
authors.initials: P
authors.lastname: Kamper
authors.forename: Maja
authors.initials: M
authors.lastname: Ludvigsen
authors.forename: Knud
authors.initials: K
authors.lastname: Bendix
authors.forename: Stephen
authors.initials: S
authors.lastname: Hamilton-Dutoit
authors.forename: Gabriel A
authors.initials: GA
authors.lastname: Rabinovich
authors.forename: Michael Boe
authors.initials: MB
authors.lastname: Møller
authors.forename: Jens R
authors.initials: JR
authors.lastname: Nyengaard
authors.forename: Bent
authors.initials: B
authors.lastname: Honoré
authors.forename: Francesco
authors.initials: F
authors.lastname: d'Amore
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism / Q000502:physiology; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D005260:Female; D037483:Galectin 1 / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007108:Immune Tolerance / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D020543:Proteome / Q000032:analysis* / Q000378:metabolism; D040901:Proteomics; D012008:Recurrence; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D037483:Galectin 1; D020543:Proteome